BioServe has acquired Genomics Collaborative from SeraCare Life Sciences, Inc. Genomics Collaborative facilitates biomarker discovery and validation through its Global Repository, a comprehensive library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 patients collected on four continents.
With this acquisition BioServe expands its preclinical product and service capabilities in drug discovery and diagnostic development with a "biomaterial to validated data" services platform. This service platform includes molecular research products and services such as DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and genotyping to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and cancers including breast, prostate, lung and colorectal, according to the company.
"The acquisition of Genomics Collaborative firmly positions BioServe as a preferred partner for preclinical discovery and validation studies. Working with BioServe, drug discovery researchers have the flexibility to tap the Bio Repository to augment their in-house sample sets, design entire genomic studies around our sample library, and further benefit from BioServe's proven ability to process and analyze vast quantities of genomic content," said Rama Modali, president, BioServe.
Genomics Collaborative will operate as a fully integrated division of BioServe. The Genomics Collaborative clinical team, led by vice president of medical affairs, George Taylor M.D., has joined BioServe.
BioServe will continue to offer the GCI Access program, which allows researchers to access human DNA, RNA, serum and tissue samples with comprehensive informed consent and detailed clinical data, on a fee for service basis.